MImAbs is a service provider platform designed to accelerate discovery and preclinical validation of new therapeutic antibodies against cancer and inflammatory diseases.

By converting promising targets from academic research, start-ups and industry into drug candidates and developing cutting-edge immunotechnologies, MImAbs enables research institutes, public technology transfer offices and biotechs to eliminate the risks associated with next-generation immunotherapies development and stay ahead of the competition. The platform delivers lead candidates with a proven high success potential in regulatory development and clinical trials.

Projects are organized on an industrial basis by multidisciplinary experts specialized in antibody discovery, biochemistry, biomanufacturing and immunopharmacology. MImAbs provides state-of-art services in many processes like B-cell based antibody discovery, and is used to work with classical mAbs, ADCs and bispecifics.